 A total of 70 subjects who had received BCG at Study Day -42 were randomized on Study Day 0 to receive 3 doses of placebo N10; 1 dose of placebo followed by 2 doses of AERAS-404 N30; AERAS-404 2 dose regimen; or 3 doses of AERAS-404 N30; AERAS-404 3 dose regimen. A total of 69 98.6 subjects completed the study; the remaining subject, in the AERAS-404 2 dose regimen, withdrew consent. All 70 subjects received the first and second vaccinations with placebo or AERAS-404 on Study Days 0 and 56, and 67 95.7 subjects received the third vaccination on Study Day 231. Three subjects did not receive the Study Day 231 vaccination 2 in the AERAS-404 2 dose regimen, 1 due to withdrawal of consent and 1 due to pregnancy the subject delivered a healthy boy without complications and was followed to study completion; and 1 in the AERAS-404 3 dose regimen, due to inability to discontinue daily isotretinoin started after the second vaccination the subject was followed to study completion. 